CytoDyn is nearing the completion of a clinical trial investigating the use of leronlimab, its repurposed and still experimental HIV drug, to treat patients with Covid-19. When results of the study read out in the next few weeks, leronlimab is unlikely to show meaningful benefit.
Should CytoDyn be trusted to offer an honest summary of its clinical trial? I have doubts. What investors may get instead is a spin job that tries to portray objectively negative study outcomes in a more positive light. Expect to see a lot of handwaving to distract from bad data.